Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 46

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 46
---
 consultant. The fees for services rendered by the compensation consultant are paid by the Company.

Beginning in September 2022, the compensation committee engaged Alpine Rewards (“Alpine”) as its independent compensation consultant. Alpine has helped to further develop our compensation programs and has advised the compensation committee on all of the principal aspects of executive compensation.

Alpine reports directly to our compensation committee and not to management, although Alpine meets with management for purposes of gathering information for its analyses and recommendations. Our compensation committee assessed the independence of Alpine consistent with Nasdaq listing standards and concluded that neither engagement raised or raises any conflict of interest.

Use of a Peer Group

The compensation committee approves a peer group of companies as a reference group to provide a broad perspective on competitive pay levels and practices. The peers are reviewed on an annual basis in light of the fast-moving changes at Denali and our industry. In August 2023, we undertook this review for use in making 2024 compensation decisions, with the assistance and recommendations of Alpine, the compensation committee’s compensation consultant. The compensation committee used the following criteria in determining the appropriate peers:

• Industry Sector and Stage – US-based, publicly traded late stage, pre-commercial stage biopharmaceutical companies and early commercial companies, where applicable, with a focus on companies with similar therapeutic focus to Denali

• Market Capitalization – Range of $1.5 billion to $12.0 billion

• Location – Biotechnology hub markets (San Francisco Bay Area, San Diego, Boston, etc.)

#### •

#### Headcount

#### – Companies with above 200 employees
2024 Peer Group

Based on these criteria and considerations, our 2024 peer group was determined to consist of the following companies:

| Agios Pharmaceuticals         |     | CRISPR Therapeutics      |     | Prothena Corporation      |
| Alector Therapeutics          |     | Cytokinetics             |     | REGENXBIO                 |
| Amylyx Pharmaceuticals        |     | Intellia Therapeutics    |     | Sage Therapeutics         |
| Arcus Biosciences             |     | Intra-Cellular Therapies |     | Sarepta Therapeutics      |
| Axsome Therapeutics           |     | Ionis Pharmaceuticals    |     | Ultragenyx Pharmaceutical |
| Beam Therapeutics             |     | Karuna Therapeutics      |     | Vaxcyte                   |
| BridgeBio Pharma              |     | Legend Biotech Corp.     |     | Vir Biotechnology         |
| C